Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H10N6.CH4O3S |
| Molecular Weight | 286.311 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1
InChI
InChIKey=DRFCWYSGNDFNPW-UHFFFAOYSA-N
InChI=1S/C8H10N6.CH4O3S/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;1-5(2,3)4/h1-4H,9-10H2,(H,11,13)(H,12,14);1H3,(H,2,3,4)
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H10N6 |
| Molecular Weight | 190.2052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Rare liver damage caused by an antihypertensive and anti-arrhythmic agents]. | 1980 Apr 1 |
|
| Side-effects with long-term labetalol: an open study of 251 patients in a single centre. | 1983 |
|
| Mode of antihypertensive action of nitrendipine. | 1984 |
|
| [Liver lesions induced by dihydralazine and propranolol]. | 1985 |
|
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | 1996 Oct-Nov |
|
| Influence of metabolic activation on the induction of micronuclei by antihypertensive drugs in L929 cells. | 2001 Feb |
|
| [When hypertension becomes an emergency case: lower the blood pressure, but slowly!]. | 2003 May 29 |
|
| The impact of maternal plasma volume expansion and antihypertensive treatment with intravenous dihydralazine on fetal and maternal hemodynamics during pre-eclampsia: a clinical, echo-Doppler and viscometric study. | 2004 Apr |
|
| Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. | 2004 Sep 21 |
|
| Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. | 2005 Jul |
|
| Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? | 2007 Dec |
|
| [Eclampsia at a teaching hospital in Ivory Coast: management, outcome and prognostic factors]. | 2008 Jul |
|
| Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis. | 2008 Jun 2 |
|
| Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | 2009 |
|
| Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. | 2009 |
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:41:57 UTC 2023
by
admin
on
Fri Dec 15 18:41:57 UTC 2023
|
| Record UNII |
9V8BVP5X5E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000078029
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
274-013-7
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
69467-96-5
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
9V8BVP5X5E
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
DTXSID70219687
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
C97309
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
SUB20331
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY | |||
|
20055439
Created by
admin on Fri Dec 15 18:41:57 UTC 2023 , Edited by admin on Fri Dec 15 18:41:57 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |